Overview

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TNP-2198 Capsules in Asymptomatic Participants With Helicobacter Pylori Infection

Status:
Completed
Trial end date:
2021-07-15
Target enrollment:
Participant gender:
Summary
This study was a Phase 1, single-center, randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and preliminary Helicobacter Pylori eradication efficacy of TNP-2198 capsules.
Phase:
Phase 1
Details
Lead Sponsor:
TenNor Therapeutics (Suzhou) Limited